Source: AIT Therapeutics, Inc.
Call scheduled for Thursday, June 14, 2018 at 8:30am Eastern Time
NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced the Board has approved a change in the Company’s fiscal year end from December 31 to March 31. The change resulted in a three-month transition period that began on January 1, 2018 and ended on March 31, 2018. The Company’s 2019 fiscal year will commence on April 1, 2018.
As a result of the change, AIT will report financial results for the three-month transition period ended March 31, 2018 and will host a conference call and webcast at 8:30am Eastern Time on Thursday, June 14, 2018.
|Conference Call & Webcast|
|Thursday, June 14th @ 8:30am Eastern Time|
|Replays available through June 28th:|
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT Therapeutics is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
Chief Executive Officer
AIT Therapeutics, Inc.
LifeSci Advisors, LLC
(646) 597 6989